Starting in 2010, LLS TAP supported a promising University of Michigan research project led by Jolanta Grembecka, PhD, to develop new treatments for patients with a rare and lethal subtype of leukemia. Through TAP, LLS engaged chemists to improve the properties that produced lead compounds that exhibited potent anti-leukemic activity. In 2014, LLS introduced Kura Oncology to the project that ultimately led to Kura Oncology completing a licensing agreement with the University of Michigan to continue to develop these molecules.
Today, Kura Oncology remains committed to developing precision medicines for cancer, and LLS TAP prior investment into this project at the University of Michigan is now supporting a "Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia."
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. KO-539, a potent and selective menin inhibitor, is currently in a Phase 1/2 clinical trial (KOMET-001) and targeting patients with relapsed/refractory acute myeloid leukemia, including patients with NPM1 mutations or KMT2A rearrangements (NCT04067336).
Preliminary clinical data of KO-539 shows promising activity in patients with relapsed or refractory AML, including patients with specific mutations. The trial also shows a favorable safety and tolerability profile, with no drug discontinuations due to treatment-related adverse events. The company is enrolling patients in a Phase 1b expansion study to assess for safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy in order to determine the recommended Phase 2 dose to support a registrational trial in the near future.
TAP Testimonial: Dr. Jolanta Grembecka, Associate Professor at The University of Michigan explains the role of LLS TAP in the early development of the KO-539 menin inhibitor.
- December 13, 2021 - announced the presentation of new preclinical data for KO-539, the Company’s oral, potent and selective menin inhibitor, and its potential for synergistic activity in combination with venetoclax, a current standard of care in the treatment of patients with acute myeloid leukemia (AML), during a poster session today at the American Society of Hematology (ASH) Annual meeting in Atlanta.
- June 24, 2021 - announced that the first patient has been dosed in the Phase 1b expansion cohort portion of KOMET-001, a Phase 1/2 clinical trial of the Company’s oral, potent and selective menin inhibitor, KO-539, in patients with relapsed or refractory acute myeloid leukemia (AML).
- Dec. 05, 2020 - announced preliminary clinical data from KOMET-001, an ongoing Phase 1/2A clinical trial of the Company’s oral, potent and selective menin inhibitor, KO-539, including single-agent activity in genetically defined subgroups of patients with relapsed or refractory acute myeloid leukemia (AML). These data are being presented during an oral session at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.